Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination with rituximab in participants with Waldenström's macroglobulinemia (WM).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02165397
Study type Interventional
Source Pharmacyclics LLC.
Contact
Status Completed
Phase Phase 3
Start date July 7, 2014
Completion date November 7, 2019

See also
  Status Clinical Trial Phase
Completed NCT00398710 - A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia Phase 2
Completed NCT01788020 - Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Phase 3
Recruiting NCT03697356 - R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia Phase 2
Completed NCT03053440 - A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) Phase 3
Recruiting NCT05979948 - A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia Phase 2
Recruiting NCT05326308 - Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma